IDDA Earnings Calls - Innate Pharma SA

Watchlist Manager

Watchlist

Price: 1.28 EUR -0.78% Market Closed

Market Cap: €103.6m

	Innate Pharma SA F:IDDA	FR
E	Euroapi SAS PAR:EAPI	FR
L	Luxxfolio Holdings Inc OTC:LUXFF	CA

Earnings Calls

Fiscal Period

Q2 2026

Call Date

Sep 17, 2026

AI Summary

Q2 2026

Lacutamab: The Sobi partnership has closed and the Phase III TELLOMAK-3 study has been initiated; the first patient is expected in Q1 2027, with an accelerated-approval filing planned for H2 2027.

IPH4502: Innate reported preliminary anti-tumor activity, including objective responses, and a favorable safety profile to date. Initial Phase I data are planned for November 18, 2026.

Monalizumab: Enrollment in the 1,051-patient PACIFIC-9 Phase III study is complete, and results are expected in H2 2026.

Funding: The $75 million Sobi upfront payment and EUR 30 million equity offering are expected to extend the cash runway through the end of Q1 2028.

Pricing: U.S. payer research indicated a potential lacutamab price of $500,000 to $625,000 per patient per year; management said the range would be supported by clinical data and an expected NCCN listing.

Key Financials

Cash, cash equivalents, and financial assets

EUR 21.4 million

Sobi upfront payment

$75 million (equivalent to EUR 65 million)

Equity offering

EUR 30 million gross proceeds; approximately EUR 28 million expected net proceeds

Sobi near-term milestones for lacutamab

Up to $40 million

Additional Sobi milestones and option-related payments

Up to $465 million

Monalizumab partnership payments received